Figure 4.
Rituximab reduces myofibroblast volume in IgG4-related disease (IgG4-RD) lesions. H&E stain of consecutive skin biopsies from a patient with cutaneous IgG4-RD involvement from the same site, before (A and B) and after (C and D) treatment with rituximab. The dermal fibroblasts (arrows) exhibit abundant cytoplasm and large nuclei in active disease, and shrink after rituximab-mediated remission (original magnification: A and C 20×, B and D 40×).